COMPANY PROFILE

Mirador Therapeutics

Explore full profile

A next-generation precision medicine company focused on immunology and inflammation

San Diego, United StatesFounded 2024Biotech & Life Sciences

Valuation $1–2.5B Last recorded · 2026

Headcount <100 Current team size

Total funding $500M–1B Disclosed equity funding

Unlock exact values

About Mirador Therapeutics

Mirador Therapeutics is a pioneering company in the field of precision medicine, focusing on immune-mediated inflammatory and fibrotic diseases. The company leverages advanced biology, multi-modal data, and sophisticated analytics to develop transformational therapies aimed at improving patient outcomes. Founded by former executives of Prometheus Biosciences, which was acquired by Merck for $10.8 billion, Mirador Therapeutics operates in the biotechnology sector. Its business model revolves around the development and commercialization of precision therapies, targeting healthcare providers and patients suffering from immune-mediated conditions. Revenue is generated through the sale of these specialized treatments and potential partnerships with larger pharmaceutical companies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2024
Headquarters: San Diego, United States
Employees: 95
Open positions: 2
Dealroom signal: 92.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Precision Medicine, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
Technology: Big Data
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Jan 2026	$250M	$2B	Farallon Capital Management · Fidelity Investments · ARCH Venture Partners · OrbiMed	↗
SERIES AOther financing	Mar 2024	$400M	$1.6B	Farallon Capital Management · ARCH Venture Partners · OrbiMed · Point72 Ventures	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Mirador Therapeutics website traffic

Latest recorded traffic for Mirador Therapeutics is 7.2K monthly website visits, up 20% over the last three months. Mirador Therapeutics's team grew 4.4% over the past year.

Latest monthly visits7.2K 3-month web change+20% 1-year team growth+4.4%

Monthly website visitsMar 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Director, ImmunologySan Diego, California, United States, Northern America, Americas · Other · Aug 27, 2026 Director, Immunology - San Diego, CASan Diego, CA · Other · Aug 27, 2026 Senior Manager, CMC – Manufacturing and R&D - San Diego, CASan Diego, California, United States, Northern America, Americas · Other · Aug 24, 2026 Executive Director, Investor Relations - San Diego, CASan Diego, California, United States, Northern America, Americas · Finance · Aug 24, 2026 Scientist, Translational Genomics - San Diego, CASan Diego, California, United States · Other · Jan 22, 2026

5 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAntares TherapeuticsDevelopment of precision oncology therapies, utilizing acquired discovery capabilities and a validated pipeline for patient treatments	Boston, United States	Operational	102	$177M	$708M
OTOdyssey TherapeuticsBuilding a machine learning-based platform to develop novel therapeutics focusing on cancer and autoimmune diseases	Boston, United States	Operational
LBLeo Summit BiotechnologyCreating a characteristic research and development platform combining "engineering center + expert think tank + postdoctoral workstation" combining production, learning and research	China	Operational
EVevidnetProvides evidence-based medicine to patients	Seoul, South Korea	Operational
DRDrugBankAI-powered pharmaceutical knowledge platform for drug development	Edmonton, Canada	Operational
PRPredxBioTissue-Based Decision Intelligence for Oncology	Bellevue, United States	Operational
CSCaris Life SciencesA profiling platform that identifies novel molecular targets to inform and enhance drug development and advanced diagnostics	Irving, United States	Operational
INInflammatixDeveloping novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system	Sunnyvale, United States	Operational